Challenges in assessing response of oesophageal cancer to neoadjuvant therapy, and the potential of composite PET-CT and multimodal metrics

Affiliations

¹ Oxford OesophagoGastric Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
² NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, UK.
³ Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
⁴ Department of Oncology, University of Oxford, Oxford, UK.

Editorial

John M Findlay et al. J Thorac Dis. 2017 Oct.

. 2017 Oct;9(10):3551-3552.

doi: 10.21037/jtd.2017.09.54.

¹ Oxford OesophagoGastric Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
² NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, UK.
³ Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
⁴ Department of Oncology, University of Oxford, Oxford, UK.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Composite metrics in response assessment-new hope in oesophageal cancer?
Włodarczyk J, Kużdżał J. Włodarczyk J, et al. J Thorac Dis. 2017 Sep;9(9):2786-2787. doi: 10.21037/jtd.2017.08.28. J Thorac Dis. 2017. PMID: 29221240 Free PMC article. No abstract available.

1. Findlay JM, Bradley KM, Wang LM, et al. Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer. Br J Surg 2017;104:408-17. 10.1002/bjs.10435 - DOI - PubMed
1. Findlay JM, Bradley KM, Wang LM, et al. Predicting pathologic response of esophageal cancer to neoadjuvant chemotherapy: the implications of metabolic nodal response for personalized therapy. J Nucl Med 2017;58:266-75. 10.2967/jnumed.116.176313 - DOI - PubMed
1. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681-92. 10.1016/S1470-2045(11)70142-5 - DOI - PubMed
1. Morgan G, Aftimos P, Awada A. Current-day precision oncology: from cancer prevention, screening, drug development, and treatment - have we fallen short of the promise? Curr Opin Oncol 2016;28:441-6. 10.1097/CCO.0000000000000318 - DOI - PubMed
1. Findlay JM, Castro-Giner F, Makino S, et al. Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. Nat Commun 2016;7:11111. 10.1038/ncomms11111 - DOI - PMC - PubMed